**Myelodysplastic Syndrome (MDS) - Adult**

**PATIENT PRESENTATION**

MDS risk based on IPSS score or IPSS-R score

- **IPSS Score of Low Risk or Intermediate I**
- **IPSS-R Score of Very Low, Low, or Intermediate**

- **IPSS Score of Intermediate II or High Risk**
- **IPSS-R Score of Intermediate, High, or Very High**

**TREATMENT**

- **Response?**
  - Yes
    - Consider clinical trials
    - Iron chelation
    - Growth factors/luspatercept
    - Hypomethylating agents
    - Lenalidomide (if 5q deletion present)
  - No
    - Allogeneic stem cell transplant
    - Clinical trials

- **Response?**
  - Yes
    - Surveillance as per protocol
  - No
    - Allogeneic stem cell transplant
    - Clinical trials

**SURVEILLANCE**

- Yes
  - Surveillance as per protocol
- No
  - Surveillance

**Disclaimer:** This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

**Note:** Consider clinical trials as treatment options for eligible patients. Leukemia patients should be referred and treated at a comprehensive cancer center.

**IPSS =** International Prognostic Scoring System
**IPSS-R =** revised International Prognostic Scoring System

1. Age ≥ 18 years
2. See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice
3. MDS risk is calculated utilizing the IPSS or IPSS-R score, which includes percent of blast, cytogenetics (consider MD Anderson approved biomarkers), and number of cytopenias
4. See Leukemia Clinical Trials
SUGGESTED READINGS


Myelodysplastic Syndrome (MDS) - Adult

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This practice algorithm is based on majority expert opinion of the Leukemia Center Faculty workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Yesid Alvarado, MD (Leukemia)
Michael Andreeff, PhD, MD (Leukemia)
Kapil Bhatta, MD (Leukemia)
Gautam Borthakur, MBBS (Leukemia)
Prithviraj Bose, MD (Leukemia)
Jan Burger, MD (Leukemia)
Naval Daver, MD (Leukemia)
Courtney DiNardo, MD (Leukemia)
Alessandra Ferrajoli, MD (Leukemia)
Emil Freireich, MD (Leukemia)
Wendy Garcia, BS*
Guillermo Garcia-Manero, MD (Leukemia)
Ghayas Issa, MD (Leukemia)
Elias Jabbour, MD (Leukemia)
Nitin Jain, MBBS (Leukemia)
Tapan Kadia, MD (Leukemia)
Hagop M. Kantarjian, MD (Leukemia)
Michael Keating, MD (Leukemia)
Marina Konopleva, PhD, MD (Leukemia)
Steven Komblaw, MD (Leukemia)
Lucia Masarova, MD (Leukemia)
Deborah M. McCue, PharmD (Pharmacy Clinical Programs)
Guillermo Montalban-Bravo, MD (Leukemia)
Maro Ohanian, DO (Leukemia)
Naveen Pemmaraju, MD (Leukemia)
Farhad Ravandi-Kashani, MD (Leukemia)
Mary Beth Rios, RN (Leukemia)
Koji Sasaki, MD (Leukemia)
Nicholas Short, MD (Leukemia)
Koichi Takahashi, MD (Leukemia)
Philip Thompson, MBBS (Leukemia)
Srđan Verstovsek, MD (Leukemia)
Mary Lou Warren, DNP, APRN, CNS-CC*
William Wierda, PhD, MD (Leukemia)
Musa Yilmaz, MD (Leukemia)

*T Core Development Leads
* Clinical Effectiveness Development Team